624 related articles for article (PubMed ID: 17409229)
1. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.
Berger Z; Roder H; Hanna A; Carlson A; Rangachari V; Yue M; Wszolek Z; Ashe K; Knight J; Dickson D; Andorfer C; Rosenberry TL; Lewis J; Hutton M; Janus C
J Neurosci; 2007 Apr; 27(14):3650-62. PubMed ID: 17409229
[TBL] [Abstract][Full Text] [Related]
2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
3. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).
Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH
J Neurosci; 2005 Nov; 25(46):10637-47. PubMed ID: 16291936
[TBL] [Abstract][Full Text] [Related]
4. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Song L; Lu SX; Ouyang X; Melchor J; Lee J; Terracina G; Wang X; Hyde L; Hess JF; Parker EM; Zhang L
Mol Neurodegener; 2015 Mar; 10():14. PubMed ID: 25881209
[TBL] [Abstract][Full Text] [Related]
5. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
Helboe L; Egebjerg J; Barkholt P; Volbracht C
Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent impairment of memory and neurofibrillary tangle formation and clearance in a mouse model of tauopathy.
Kubota T; Kirino Y
Brain Res; 2021 Aug; 1765():147496. PubMed ID: 33894222
[TBL] [Abstract][Full Text] [Related]
7. Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration.
De Jesús-Cortés HJ; Nogueras-Ortiz CJ; Gearing M; Arnold SE; Vega IE
Neuroreport; 2012 Nov; 23(16):942-6. PubMed ID: 22975846
[TBL] [Abstract][Full Text] [Related]
8. Visual Evoked Potentials as an Early-Stage Biomarker in the rTg4510 Tauopathy Mouse Model.
Parka A; Volbracht C; Hall B; Bastlund JF; Nedergaard M; Laursen B; Botta P; Sotty F
J Alzheimers Dis; 2023; 93(1):247-262. PubMed ID: 37005884
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
10. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
11. Analysis of in vivo turnover of tau in a mouse model of tauopathy.
Yamada K; Patel TK; Hochgräfe K; Mahan TE; Jiang H; Stewart FR; Mandelkow EM; Holtzman DM
Mol Neurodegener; 2015 Oct; 10():55. PubMed ID: 26502977
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tauopathies with transgenic mice.
Hutton M; Lewis J; Dickson D; Yen SH; McGowan E
Trends Mol Med; 2001 Oct; 7(10):467-70. PubMed ID: 11597522
[TBL] [Abstract][Full Text] [Related]
13. Progressive Pathological Changes in Neurochemical Profile of the Hippocampus and Early Changes in the Olfactory Bulbs of Tau Transgenic Mice (rTg4510).
Kim J; Choi IY; Duff KE; Lee P
Neurochem Res; 2017 Jun; 42(6):1649-1660. PubMed ID: 28523532
[TBL] [Abstract][Full Text] [Related]
14. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
[TBL] [Abstract][Full Text] [Related]
15. Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease.
Vega IE; Umstead A; Wygant CM; Beck JS; Counts SE
Curr Alzheimer Res; 2018; 15(12):1086-1095. PubMed ID: 30101710
[TBL] [Abstract][Full Text] [Related]
16. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
[TBL] [Abstract][Full Text] [Related]
17. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
18. CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy.
Joly-Amado A; Hunter J; Quadri Z; Zamudio F; Rocha-Rangel PV; Chan D; Kesarwani A; Nash K; Lee DC; Morgan D; Gordon MN; Selenica MB
Front Immunol; 2020; 11():997. PubMed ID: 32508844
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
20. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model.
Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD
Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
